C
Cedilla Therapeutics
Harnessing intrinsic protein stability mechanisms to develop small molecule therapeutics for cancer and protein dysregulation diseases
About Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company focused on developing small molecule therapeutics by leveraging intrinsic protein stability mechanisms. The company primarily targets diseases caused by protein dysregulation, including various forms of cancer. Cedilla operates in the biotech and pharmaceutical market, serving patients who suffer from these complex diseases. The business model revolves around drug discovery and development, with a focus on creating effective treatments that address unmet medical needs. Revenue is generated through the development and commercialization of these therapeutics, often in partnership with larger pharmaceutical companies. Cedilla's team is composed of highly motivated scientists and researchers dedicated to advancing oncology programs and other therapeutic areas. The company is headquartered in Cambridge, MA, a hub for biotech innovation, and benefits from a rich network of industry connections and resources.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- Cambridge, United States
- Employees
- 6
- Open positions
- None listed
- Dealroom signal
- 59.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Biotech and Pharma, proteomics, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Oct 2021 | $25M | $288M | Woodline Partners · RA Capital Management · Janus Henderson Investors · Logos Capital | ↗ |
| SERIES BOther financing | Oct 2020 | $58M | $230M | Third Rock Ventures · Eli Lilly · Boxer Capital · Tavistock Group | — |
Growth signals
Latest recorded traffic for Cedilla Therapeutics is 650 monthly website visits, up 18.2% over the last three months. Cedilla Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A10 investors entered at this stage
Third Rock Ventures
Tavistock Group
Casdin Capital
Eli Lilly
Boxer Capital
Schroder Adveq
RA Capital Management
Woodline Partners
Janus Henderson Investors
Logos Capital
Other known investors3 additional known investors
Dana-Farber Cancer Institute
Harvard Medical School
University of California, San Francisco
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cedilla Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cedilla Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.